ES2139667T3 - Peptidos sinteticos para el tratamiento de la miastenia gravis. - Google Patents

Peptidos sinteticos para el tratamiento de la miastenia gravis.

Info

Publication number
ES2139667T3
ES2139667T3 ES93916644T ES93916644T ES2139667T3 ES 2139667 T3 ES2139667 T3 ES 2139667T3 ES 93916644 T ES93916644 T ES 93916644T ES 93916644 T ES93916644 T ES 93916644T ES 2139667 T3 ES2139667 T3 ES 2139667T3
Authority
ES
Spain
Prior art keywords
treatment
different
synthetic peptides
peptides
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93916644T
Other languages
English (en)
Inventor
Michael Sela
Edna Mozes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of ES2139667T3 publication Critical patent/ES2139667T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE DESCUBREN PEPTIDOS QUE TIENEN AL MENOS NUEVE RESIDUOS AMINOACIDOS QUE INCLUYEN CADA UNO UNA SECUENCIA AMINOACIDA QUE CORRESPONDE A LA POSICION P200-208 O P262-266 DE LA SUBUNIDAD ALFA RECEPTORA DE ACETILCOLINA HUMANA, PERO QUE DIFIEREN POR UNA O MAS SUSTITUCIONES AMINOACIDAS.ESTOS PEPTIDOS INHIBEN LA RESPUESTA PROLIFERATIVA DE LIMFOCITOS PERIFERICOS DE LA SANGRE HUMANOS A LOS PEPTIDOS MIASTOGENICOS P195-21 Y P259-271 Y SON ADECUADOS PARA EL TRATAMIENTO DE SUJETOS AFECTADOS DE MIASTENIA GRAVIS.
ES93916644T 1992-06-18 1993-06-18 Peptidos sinteticos para el tratamiento de la miastenia gravis. Expired - Lifetime ES2139667T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90039392A 1992-06-18 1992-06-18

Publications (1)

Publication Number Publication Date
ES2139667T3 true ES2139667T3 (es) 2000-02-16

Family

ID=25412446

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93916644T Expired - Lifetime ES2139667T3 (es) 1992-06-18 1993-06-18 Peptidos sinteticos para el tratamiento de la miastenia gravis.

Country Status (11)

Country Link
EP (1) EP0646016B1 (es)
JP (1) JP3996635B2 (es)
AT (1) ATE183652T1 (es)
AU (1) AU678372B2 (es)
CA (1) CA2138258C (es)
DE (1) DE69326145T2 (es)
DK (1) DK0646016T3 (es)
ES (1) ES2139667T3 (es)
GR (1) GR3031371T3 (es)
IL (3) IL106065A (es)
WO (1) WO1994000148A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066621A (en) * 1989-12-10 2000-05-23 Yeda Research And Development Co. Ltd. Synthetic peptides for the treatment of myasthenia gravis
US5843462A (en) * 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
CA2315537A1 (en) 1997-12-16 1999-06-24 Regents Of The University Of Minnesota Methods to treat undesirable immune responses
CA2336238A1 (en) 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
US20240270816A1 (en) 2021-06-07 2024-08-15 Toleranzia Ab Fusion protein for treating myasthenia gravis
CN121175067A (zh) * 2023-03-24 2025-12-19 库尔制药开发公司 用于重症肌无力治疗的耐受性免疫修饰纳米颗粒

Also Published As

Publication number Publication date
EP0646016A4 (en) 1995-07-12
ATE183652T1 (de) 1999-09-15
WO1994000148A1 (en) 1994-01-06
JPH07508521A (ja) 1995-09-21
JP3996635B2 (ja) 2007-10-24
IL122445A (en) 2000-08-31
DE69326145T2 (de) 2000-04-27
IL106065A0 (en) 1993-10-20
CA2138258A1 (en) 1994-01-06
AU4642993A (en) 1994-01-24
EP0646016B1 (en) 1999-08-25
GR3031371T3 (en) 2000-01-31
EP0646016A1 (en) 1995-04-05
IL122445A0 (en) 1998-06-15
IL106065A (en) 1999-10-28
DK0646016T3 (da) 2000-03-20
DE69326145D1 (de) 1999-09-30
AU678372B2 (en) 1997-05-29
CA2138258C (en) 2003-08-19

Similar Documents

Publication Publication Date Title
ES2038571T1 (es) Procedimiento de preparacion de anticuerpos monoclonales especificos de las interleucinas 1alfa y 1beta.
ES2133271T3 (es) Receptores para factores de crecimiento de fibroblastos.
ATE307827T1 (de) Respiratorisches syncytialvirus; impfstoffe und diagnostische tests
DK164088A (da) Syntetiske peptidantigener til paavisning af hiv-1-infektion
DE69233772D1 (de) T-zell epitopen von den wichtigsten allergene von dermatophagoides (hausmilbe)
MX163592B (es) Compuestos de polipeptido que tienen actividad liberadora de la hormona del crecimiento
NO821111L (no) Radioaktivt merkede peptider
DK1082128T3 (da) Lysinholdige peptider til behandling af hjertesygdom
ES2115622T3 (es) Clones moleculares de hiv-1 y usos de los mismos.
ES2139667T3 (es) Peptidos sinteticos para el tratamiento de la miastenia gravis.
AR002949A1 (es) Análogos del peptido p277 y composiciónes farmaceuticas y preparaciónes que los comprenden para el tratamiento o diagnostico de diabetes y un equipo para diagnosticar.
ES2166770T3 (es) Anticuerpos monoclonales contra gangliosidos y sus utilizaciones en la inmunoterapia activa especifica de tumores malignos.
MX9301675A (es) Composiciones que contienen peptidos para inducir tolerancia de las celulas t a un antigeno.
DE69109824D1 (de) Verfahren zur Untersuchung des Bewegungssystems des Auges.
SE8403377L (sv) Nya peptider
ES2061495T3 (es) Peptidos relacionados con el virus htlv-iii, anticuerpos para los peptidos, vacunas, inmunizacion activa y pasiva contra el virus del sida y prueba diagnostica para la deteccion serologica del virus del sida.
DE69333709D1 (de) T-zell epitope des raygraspollen-allergens
DE69636881D1 (de) Stereoisomere von fettsäureanalogen zur diagnostischen bildgebung
ES2057579T3 (es) Peptidos e1 y c de rubeola.
DE69607962D1 (de) Synthetische peptide und diese enthaltende pharmazeutische zusammensetzungen
DK0422215T3 (da) Antibakterielle peptider og antimalariapeptider
ATE98962T1 (de) Menschliche rhinoviruspeptide.
DE69323688D1 (de) Epitop-Peptide von menschlichem Parvovirus
ES2061908T3 (es) Antagonistas competitivos de gonadoliberina.
EP0697112A4 (en) C-TERMINAL SEQUENCING OF PEPTIDES THAT MAY CONTAIN PROLIN

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 646016

Country of ref document: ES